ストックスクリーナーアプリを入手
20.68
6.76%
-1.50
アフターアワーズ：
20.69
0.01
+0.05%
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - simplywall.st
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - 기업경제뉴스
Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha
Acadia push in ADP still alive after near miss in phase II - BioWorld News
Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says - finance.yahoo.com
ACAD Maintains Buy Rating -- Price Target Lowered to $33.00 by HC Wainwright - GuruFocus
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - finance.yahoo.com
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss - finance.yahoo.com
ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co. - Moomoo
HC Wainwright & Co. maintains Buy rating on ACADIA Pharmaceuticals, $33 price target - TradingView
Needham cuts Acadia Pharmaceuticals stock price target on trial results By Investing.com - Investing.com Nigeria
Citizens maintains Market Outperform rating on ACADIA Pharmaceuticals, $33 price target - TradingView
Needham cuts Acadia Pharmaceuticals stock price target on trial results - Investing.com India
ACAD Maintained by Needham -- Price Target Lowered to $35 - GuruFocus
Citizens cuts Acadia Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office - ROI-NJ
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13% - finance.yahoo.com
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - tikr.com
Acadia Alters Phase III Trials To Help Remlifanserin Succeed In Alzheimer’s Psychosis - insights.citeline.com
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20% - finance.yahoo.com
Acadia Reports Phase 2 Data for Alzheimer’s Psychosis - TipRanks
Acadia reports Phase 3-enabling Phase 2 topline for remlifanserin in AD psychosis; 60 mg shows nominal CGI-S significance - TradingView
Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily
ACADIA Pharma's price target cut after mixed Al... - Pluang
Goldman Sachs reiterates Acadia Pharmaceuticals stock Sell rating after trial miss - Investing.com Canada
TD Cowen reiterates Acadia Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease PsychosisSlideshow (NASDAQ:ACAD) 2026-09-24 - Seeking Alpha
Why Is Acadia Pharmaceuticals Stock Tumbling Today?ACADIA Pharmaceuticals (NASDAQ:ACAD) - benzinga.com
BMO cuts Acadia Pharmaceuticals stock price target on trial miss - Investing.com
BMO cuts Acadia Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Acadia shares drop 9% after mixed Phase 2 resul... - Pluang
Acadia Pharmaceuticals: Remlifanserin Is In Trouble (NASDAQ:ACAD) - Seeking Alpha
ACADIA Pharmaceuticals (ACAD) Reiterated by Needham -- Price Tar - GuruFocus
ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25 - AlphaStreet
Acadia's Alzheimer's psychosis drug remlifanserin posts Phase 3-enabling Phase 2 results - app.dealroom.co
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data - Yahoo Finance
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial - finance.yahoo.com
Acadia drug fails mid-stage study in Alzheimer’s psychosis, leading to modified Phase 3 - Endpoints News
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward - BioSpace
Why is ACADIA Pharmaceuticals stock tumbling today? By Investing.com - Investing.com Canada
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint - finance.yahoo.com
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing - Fierce Biotech
Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday - Yahoo Finance
Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy - TradingView
Why is ACADIA Pharmaceuticals stock sliding today? By Investing.com - Investing.com Canada
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study - marketscreener.com
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint - marketscreener.com
ACAD Looks 0.8% Undervalued on GF Value™ as Clinical Trial Progr - GuruFocus
Acadia reports phase 2 results for Alzheimer’s psychosis drug - Investing.com
Acadia Pharmaceuticals stock tumbles on mixed trial results By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals stock tumbles on mixed trial results - Investing.com
A second measure favored the higher dose. The Alzheimer’s drug narrowly missed its main test. - stocktitan.net
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - sg.finance.yahoo.com
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo! Finance Canada
Acadia Pharmaceuticals Announces Phase 3 Enabli… | UNI India - uniindia.com
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits
Acadia Pharma (ACAD): Will Remlifanserin Data Unlock A New Growth Opportunity? - RTTNews
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Form 8K ACADIA Pharmaceuticals Inc For: 11 September By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action - Investing.com
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):